Asset
fosifloxuridine nafalbenamide
NuCana plc American Depositary Share
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03428958 | phase1_2 | completed | 2018-10-05 | 2024-03-19 | NuCana plc | A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment |
FDA applications (0)
This company has no applications containing this asset.